Your shopping cart is currently empty

HEPPS exhibits inhibitory activity against the amyloid-beta precursor protein, reducing Aβ aggregation burden and improving neuronal autophagy flux, thereby alleviating neuronal apoptosis and traumatic brain injury (TBI) in mice. It can be used for research into Alzheimer's disease and neurological disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 50 g | $31 | - | In Stock | |
| 100 g | $45 | - | In Stock |
| Description | HEPPS exhibits inhibitory activity against the amyloid-beta precursor protein, reducing Aβ aggregation burden and improving neuronal autophagy flux, thereby alleviating neuronal apoptosis and traumatic brain injury (TBI) in mice. It can be used for research into Alzheimer's disease and neurological disorders. |
| In vivo | Methods: A mouse model of traumatic brain injury (TBI) was established using controlled cortical impact (CCI). HEPPS was administered orally at a dose of 120 mg/kg immediately after injury and then once daily for 3 or 7 days. Aβ accumulation, autophagy, apoptosis, and neurological function were evaluated through histological and molecular analyses. A chloroquine-treated group was included to assess whether the effects of HEPPS were mediated through autophagy. Results: HEPPS significantly reduced Aβ accumulation and axonal injury in the brain after TBI, improved synaptic function and autophagic flux, decreased neuronal apoptosis, prevented brain tissue loss, and enhanced motor and cognitive functions. These protective effects were partially reversed by chloroquine treatment, suggesting that the neuroprotective effect of HEPPS is associated with enhanced autophagy [1]. |
| Molecular Weight | 252.33 |
| Formula | C9H20N2O4S |
| Cas No. | 16052-06-5 |
| Smiles | O=S(=O)(O)CCCN1CCN(CCO)CC1 |
| Relative Density. | 1.285g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 200 mg/mL (792.61 mM), Sonication is recommended. DMSO: 1 mg/mL (3.96 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
H2O
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.